Adaptive Biotechnologies (NASDAQ:ADPT) Insider Susan Bobulsky Sells 5,000 Shares of Stock

Posted by Francis Steltz on Jun 16th, 2026

Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) insider Susan Bobulsky sold 5,000 shares of the company’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $19.00, for a total transaction of $95,000.00. Following the sale, the insider directly owned 411,775 shares of the company’s stock, valued at approximately $7,823,725. This represents a 1.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Susan Bobulsky also recently made the following trade(s):

On Thursday, June 4th, Susan Bobulsky sold 11,000 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $18.00, for a total transaction of $198,000.00.

Adaptive Biotechnologies Price Performance

Shares of ADPT opened at $17.46 on Tuesday. The company has a market capitalization of $2.79 billion, a PE ratio of -52.91 and a beta of 2.16. Adaptive Biotechnologies Corporation has a one year low of $9.96 and a one year high of $20.76. The company’s fifty day moving average price is $14.62 and its 200 day moving average price is $15.63.

Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. The company had revenue of $70.87 million during the quarter, compared to analysts’ expectations of $61.03 million. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The business’s quarterly revenue was up 35.1% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.20) earnings per share. Analysts anticipate that Adaptive Biotechnologies Corporation will post -0.47 earnings per share for the current year.

Institutional Trading of Adaptive Biotechnologies

Hedge funds have recently modified their holdings of the company. Westfield Capital Management Co. LP acquired a new stake in shares of Adaptive Biotechnologies during the 4th quarter worth approximately $65,942,000. Price T Rowe Associates Inc. MD raised its stake in shares of Adaptive Biotechnologies by 303.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock valued at $71,252,000 after purchasing an additional 3,299,635 shares in the last quarter. Ameriprise Financial Inc. lifted its position in Adaptive Biotechnologies by 84.3% in the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after purchasing an additional 2,731,648 shares during the period. Invesco Ltd. lifted its position in Adaptive Biotechnologies by 248.8% in the fourth quarter. Invesco Ltd. now owns 3,107,653 shares of the company’s stock worth $50,468,000 after purchasing an additional 2,216,595 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its stake in Adaptive Biotechnologies by 544.0% during the third quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock worth $36,523,000 after buying an additional 2,062,282 shares in the last quarter. Institutional investors own 99.17% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on ADPT. Morgan Stanley dropped their price target on Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. BTIG Research reissued a “buy” rating and issued a $22.00 price objective on shares of Adaptive Biotechnologies in a research report on Wednesday, May 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Monday, April 20th. Guggenheim reaffirmed a “buy” rating and set a $21.00 target price on shares of Adaptive Biotechnologies in a research report on Wednesday, May 6th. Finally, JPMorgan Chase & Co. cut their target price on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $19.57.

Check Out Our Latest Analysis on Adaptive Biotechnologies

Adaptive Biotechnologies Company Profile

(Get Free Report)

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.